Saracatinib Inhibits Necroptosis and Ameliorates Psoriatic Inflammation by Targeting MLKL

In an imiquimod-induced psoriasis mouse model, saracatinib effectively blocked mixed lineage kinase domain-like protein (MLKL) phosphorylation and inflammatory responses in vivo.